Cargando…
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59642/ https://www.ncbi.nlm.nih.gov/pubmed/11806788 http://dx.doi.org/10.1186/cvm-2-4-151 |
_version_ | 1782120092196143104 |
---|---|
author | Bonarjee, Vernon VS Dickstein, Kenneth |
author_facet | Bonarjee, Vernon VS Dickstein, Kenneth |
author_sort | Bonarjee, Vernon VS |
collection | PubMed |
description | Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been known. The results from the Heart Outcome Prevention Evaluation trial have indicated that long-term treatment with ramipril leads to a significant reduction in cardiovascular events in patients with atherosclerotic disease, including those with prior myocardial infarction and preserved LV function. These results suggest that long-term angiotensin-converting enzyme inhibition should also be considered in post-infarction patients with normal cardiac function. |
format | Text |
id | pubmed-59642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-596422001-11-06 How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial Bonarjee, Vernon VS Dickstein, Kenneth Curr Control Trials Cardiovasc Med Commentary Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been known. The results from the Heart Outcome Prevention Evaluation trial have indicated that long-term treatment with ramipril leads to a significant reduction in cardiovascular events in patients with atherosclerotic disease, including those with prior myocardial infarction and preserved LV function. These results suggest that long-term angiotensin-converting enzyme inhibition should also be considered in post-infarction patients with normal cardiac function. BioMed Central 2001 2001-06-26 /pmc/articles/PMC59642/ /pubmed/11806788 http://dx.doi.org/10.1186/cvm-2-4-151 Text en Copyright © 2001 BioMed Central Ltd |
spellingShingle | Commentary Bonarjee, Vernon VS Dickstein, Kenneth How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial |
title | How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial |
title_full | How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial |
title_fullStr | How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial |
title_full_unstemmed | How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial |
title_short | How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial |
title_sort | how long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the hope trial |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59642/ https://www.ncbi.nlm.nih.gov/pubmed/11806788 http://dx.doi.org/10.1186/cvm-2-4-151 |
work_keys_str_mv | AT bonarjeevernonvs howlongshouldangiotensinconvertingenzymeinhibitorsbegiventopatientsfollowingmyocardialinfarctionimplicationsofthehopetrial AT dicksteinkenneth howlongshouldangiotensinconvertingenzymeinhibitorsbegiventopatientsfollowingmyocardialinfarctionimplicationsofthehopetrial |